S&P 500   3,343.98 (-0.23%)
DOW   27,511.49 (-0.26%)
QQQ   276.45 (-0.27%)
AAPL   114.06 (-0.78%)
MSFT   207.39 (-0.98%)
FB   259.32 (+0.97%)
GOOGL   1,458.87 (+0.01%)
AMZN   3,162.97 (-0.35%)
TSLA   425.64 (+1.05%)
NVDA   533.82 (+2.38%)
BABA   277.06 (+0.38%)
CGC   14.49 (+1.97%)
GE   6.07 (-2.10%)
MU   50.97 (+2.51%)
AMD   82.32 (+3.57%)
T   28.23 (-0.53%)
F   6.60 (-1.35%)
ACB   4.84 (+1.26%)
GILD   62.10 (-1.19%)
NFLX   494.76 (+0.84%)
DIS   124.11 (-1.49%)
BA   163.15 (-1.76%)
BAC   23.76 (-1.37%)
S&P 500   3,343.98 (-0.23%)
DOW   27,511.49 (-0.26%)
QQQ   276.45 (-0.27%)
AAPL   114.06 (-0.78%)
MSFT   207.39 (-0.98%)
FB   259.32 (+0.97%)
GOOGL   1,458.87 (+0.01%)
AMZN   3,162.97 (-0.35%)
TSLA   425.64 (+1.05%)
NVDA   533.82 (+2.38%)
BABA   277.06 (+0.38%)
CGC   14.49 (+1.97%)
GE   6.07 (-2.10%)
MU   50.97 (+2.51%)
AMD   82.32 (+3.57%)
T   28.23 (-0.53%)
F   6.60 (-1.35%)
ACB   4.84 (+1.26%)
GILD   62.10 (-1.19%)
NFLX   494.76 (+0.84%)
DIS   124.11 (-1.49%)
BA   163.15 (-1.76%)
BAC   23.76 (-1.37%)
S&P 500   3,343.98 (-0.23%)
DOW   27,511.49 (-0.26%)
QQQ   276.45 (-0.27%)
AAPL   114.06 (-0.78%)
MSFT   207.39 (-0.98%)
FB   259.32 (+0.97%)
GOOGL   1,458.87 (+0.01%)
AMZN   3,162.97 (-0.35%)
TSLA   425.64 (+1.05%)
NVDA   533.82 (+2.38%)
BABA   277.06 (+0.38%)
CGC   14.49 (+1.97%)
GE   6.07 (-2.10%)
MU   50.97 (+2.51%)
AMD   82.32 (+3.57%)
T   28.23 (-0.53%)
F   6.60 (-1.35%)
ACB   4.84 (+1.26%)
GILD   62.10 (-1.19%)
NFLX   494.76 (+0.84%)
DIS   124.11 (-1.49%)
BA   163.15 (-1.76%)
BAC   23.76 (-1.37%)
S&P 500   3,343.98 (-0.23%)
DOW   27,511.49 (-0.26%)
QQQ   276.45 (-0.27%)
AAPL   114.06 (-0.78%)
MSFT   207.39 (-0.98%)
FB   259.32 (+0.97%)
GOOGL   1,458.87 (+0.01%)
AMZN   3,162.97 (-0.35%)
TSLA   425.64 (+1.05%)
NVDA   533.82 (+2.38%)
BABA   277.06 (+0.38%)
CGC   14.49 (+1.97%)
GE   6.07 (-2.10%)
MU   50.97 (+2.51%)
AMD   82.32 (+3.57%)
T   28.23 (-0.53%)
F   6.60 (-1.35%)
ACB   4.84 (+1.26%)
GILD   62.10 (-1.19%)
NFLX   494.76 (+0.84%)
DIS   124.11 (-1.49%)
BA   163.15 (-1.76%)
BAC   23.76 (-1.37%)
Log in
NASDAQ:IDYA

IDEAYA Biosciences Stock Forecast, Price & News

$11.80
-0.39 (-3.20 %)
(As of 09/29/2020 01:30 PM ET)
Add
Compare
Today's Range
$11.31
Now: $11.80
$11.94
50-Day Range
$11.22
MA: $11.99
$13.31
52-Week Range
$2.95
Now: $11.80
$19.97
Volume3,721 shs
Average Volume157,296 shs
Market Capitalization$342.53 million
P/E RatioN/A
Dividend YieldN/A
Beta2.43
IDEAYA Biosciences, Inc., an oncology-focused precision medicine company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's product candidate in clinical development is IDE196, a protein kinase C inhibitor for genetically-defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting MAT2A in tumor cells having MTAP gene deletions; Pol-theta in tumors with genetic mutations in homologous recombination deficiency, including BRCA mutations; PARG in tumors with genetic mutations in base excision repair; and WRN in high microsatellite instability tumors. The company was founded in 2015 and is headquartered in South San Francisco, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.04 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:IDYA
CUSIPN/A
CIKN/A
Phone650-443-6209

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$4.94 per share

Profitability

Net Income$-41,970,000.00

Miscellaneous

Employees56
Market Cap$342.53 million
Next Earnings Date11/11/2020 (Estimated)
OptionableNot Optionable
$11.80
-0.39 (-3.20 %)
(As of 09/29/2020 01:30 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive IDYA News and Ratings via Email

Sign-up to receive the latest news and ratings for IDYA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











IDEAYA Biosciences (NASDAQ:IDYA) Frequently Asked Questions

How has IDEAYA Biosciences' stock been impacted by Coronavirus?

IDEAYA Biosciences' stock was trading at $4.85 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, IDYA shares have increased by 143.3% and is now trading at $11.80.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of IDEAYA Biosciences?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IDEAYA Biosciences in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for IDEAYA Biosciences
.

When is IDEAYA Biosciences' next earnings date?

IDEAYA Biosciences is scheduled to release its next quarterly earnings announcement on Wednesday, November 11th 2020.
View our earnings forecast for IDEAYA Biosciences
.

How were IDEAYA Biosciences' earnings last quarter?

IDEAYA Biosciences (NASDAQ:IDYA) posted its quarterly earnings data on Wednesday, August, 12th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.83 by $2.42.
View IDEAYA Biosciences' earnings history
.

What price target have analysts set for IDYA?

5 analysts have issued 1-year target prices for IDEAYA Biosciences' shares. Their forecasts range from $12.00 to $28.00. On average, they expect IDEAYA Biosciences' stock price to reach $23.00 in the next twelve months. This suggests a possible upside of 94.9% from the stock's current price.
View analysts' price targets for IDEAYA Biosciences
.

Who are some of IDEAYA Biosciences' key competitors?

What other stocks do shareholders of IDEAYA Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IDEAYA Biosciences investors own include Aldeyra Therapeutics (ALDX), Opko Health (OPK), Sorrento Therapeutics (SRNE), Fulcrum Therapeutics (FULC), VBI Vaccines (VBIV), NVIDIA (NVDA), Boeing (BA), InVitae (NVTA), Xeris Pharmaceuticals (XERS) and Entasis Therapeutics (ETTX).

Who are IDEAYA Biosciences' key executives?

IDEAYA Biosciences' management team includes the following people:
  • Mr. Yujiro S. Hata, Co-Founder, CEO, Pres & Director (Age 45)
  • Mr. Jeffrey Hager, Sr. VP, CTO, Head of Target Discovery & External Innovation (Age 55)
  • Mr. Paul A. Stone, Sr. VP, Gen. Counsel & Head of Operations (Age 55)
  • Mr. Michael P. Dillon, Sr. VP, Chief Scientific Officer & Head of Research (Age 52)
  • Dr. Julie Hambleton, Sr. VP, Chief Medical Officer & Head of Devel. (Age 61)

When did IDEAYA Biosciences IPO?

(IDYA) raised $70 million in an IPO on Thursday, May 23rd 2019. The company issued 5,000,000 shares at $13.00-$15.00 per share. J.P. Morgan, Citigroup and Jefferies acted as the underwriters for the IPO.

What is IDEAYA Biosciences' stock symbol?

IDEAYA Biosciences trades on the NASDAQ under the ticker symbol "IDYA."

How do I buy shares of IDEAYA Biosciences?

Shares of IDYA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is IDEAYA Biosciences' stock price today?

One share of IDYA stock can currently be purchased for approximately $11.80.

How big of a company is IDEAYA Biosciences?

IDEAYA Biosciences has a market capitalization of $342.53 million. The company earns $-41,970,000.00 in net income (profit) each year or ($3.36) on an earnings per share basis. IDEAYA Biosciences employs 56 workers across the globe.

What is IDEAYA Biosciences' official website?

The official website for IDEAYA Biosciences is www.ideayabio.com.

How can I contact IDEAYA Biosciences?

IDEAYA Biosciences' mailing address is 7000 SHORELINE COURT SUITE 350, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-443-6209 or via email at [email protected]

This page was last updated on 9/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.